Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI571 in HES and Eosinophilic Leukemias
NCT00276926Phase 2Unknown
- Sponsor
- Alma Mater Studiorum – Università di Bologna
- Start
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL) and myeloproliferative neoplasms (MPN), sponsored by Alma Mater Studiorum – Università di Bologna. Primary endpoint: Complete Response Rate at 3 months. Status: unknown.
02
Drugs
03
Conditions
hypereosinophilic syndrome (HES)chronic eosinophilic leukemia (CEL)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT00276926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276926.